Literature DB >> 29937384

Recurrent Pericardial Effusion While Receiving Nivolumab for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature.

Alexander Vittorio1, Rajiv Sharma2, Dylan Siejka2, Keshav Bhattarai2, Ashutosh Hardikar2.   

Abstract

Entities:  

Keywords:  Checkpoint; Immune; Pericardiocentesis; Tamponade; Window

Mesh：

Substances：

Year:  2018        PMID： 29937384     DOI： 10.1016/j.cllc.2018.05.010

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  8 in total

1.  Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports.

Authors:  Alessandro Inno; Nicola Maurea; Giulio Metro; Andreina Carbone; Antonio Russo; Stefania Gori
Journal:  Cancer Immunol Immunother       Date:  2021-04-20       Impact factor: 6.968

2.  Would the Addition of Immunotherapy Impact the Prognosis of Patients With Malignant Pericardial Effusion?

Authors:  Varsha Chiruvella; Asad Ullah; Islam Elhelf; Nikhil Patel; Nagla Abdel Karim
Journal:  Front Oncol       Date:  2022-05-06       Impact factor: 5.738

Review 3.  Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer.

Authors:  Magdalena Zaborowska-Szmit; Maciej Krzakowski; Dariusz M Kowalski; Sebastian Szmit
Journal:  J Clin Med       Date:  2020-04-27       Impact factor: 4.241

4.  Pericardial Effusion With Tamponade in Lung Cancer Patients During Treatment With Nivolumab: A Report of Two Cases.

Authors:  Masahiro Yamasaki; Wakako Daido; Naomi Saito; Kunihiko Funaishi; Takenori Okada; Kazuma Kawamoto; Yu Matsumoto; Naoko Matsumoto; Masaya Taniwaki; Nobuyuki Ohashi; Noboru Hattori
Journal:  Front Oncol       Date:  2019-01-22       Impact factor: 6.244

5.  Pericardial effusion under nivolumab: case-reports and review of the literature.

Authors:  Anastasia Saade; Audrey Mansuet-Lupo; Jennifer Arrondeau; Constance Thibault; Mariana Mirabel; François Goldwasser; Stéphane Oudard; Laurence Weiss
Journal:  J Immunother Cancer       Date:  2019-10-18       Impact factor: 13.751

Review 6.  Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature.

Authors:  Kazuaki Harada; Makoto Ogasawara; Akane Shido; Akimitsu Meno; Soichiro Oda; Shota Yoshida; Sonoe Yoshida; Ayumu Yoshikawa; Ko Ebata; Satoshi Abiko; Naoki Kawagishi; Itsuki Sano; Hisashi Oda; Takuto Miyagishima
Journal:  Thorac Cancer       Date:  2020-03-17       Impact factor: 3.500

Review 7.  Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity.

Authors:  Vickie R Shannon; Ronald Anderson; Ada Blidner; Jennifer Choi; Tim Cooksley; Michael Dougan; Ilya Glezerman; Pamela Ginex; Monica Girotra; Dipti Gupta; Douglas B Johnson; Maria E Suarez-Almazor; Bernardo L Rapoport
Journal:  Support Care Cancer       Date:  2020-09-03       Impact factor: 3.603

8.  Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab.

Authors:  Ryo Sawada; Yohei Matsui; Junji Uchino; Naoko Okura; Yoshie Morimoto; Masahiro Iwasaku; Yoshiko Kaneko; Tadaaki Yamada; Koichi Takayama
Journal:  Intern Med       Date:  2021-06-05       Impact factor: 1.271
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.